Stifel analyst Jonathan Block said IntriCon (IIN) remains one of his highest conviction ideas and he contends that the stock seems oversold at current levels. After "a wild ride in 2018," the stock is trading at a discount to other value added suppliers even after zeroing out any valuation at all for Hearing, noted Block, who said this is despite IntriCon possessing a greater top-line growth profile and superior long-term margin structure than Medical peers such as Integer (ITGR) and Novanta (NOVT). Block keeps a Buy rating on IntriCon shares, though he lowered his price target on the stock to $45 from $70.